Numbers

Claude View

The Numbers

Carysil trades at ~29x trailing earnings and ~198x FY25 free cash flow because the market is pricing the FY26 margin recovery, not the FY25 capital inefficiency. The single metric most likely to rerate or derate the stock is free cash flow conversion — reported profit was ₹64 Cr in FY25 but FCF was only ₹13 Cr, the rest vanished into a working-capital build that is either temporary inventory positioning for the tariff whiplash or structural capital trapping. Q4 FY26 will tell us which.

Valuation snapshot

The stock has doubled off the ₹582 tariff-scare low and sits ~15% off the ₹1,072 post-tariff-cut high. MNCL carries BUY, target ₹1,190 (FY28E rollover). On FY25 reported earnings the stock is 40x; only the 9M FY26 NI surge (₹71 Cr, already above full-year FY25's ₹64 Cr) drags the multiple back to the mid-twenties.

Revenue and earnings power — the 11-year arc

Revenue compounded at 20.5% CAGR over 11 years, net income at ~23% — but net income has flatlined at ₹53–65 Cr since FY22 even as revenue doubled. A classic capex-cycle compression: depreciation and interest walked up in lockstep with the asset base, eating every rupee of operating leverage.

Margin story — the resin, not the volume

Op margin compressed ~500 bps from FY22's 22% to FY25's 17%. The FY26 bounce to 19% is real but single-source — cheaper imported quartz resin, not volume leverage. Net margin is still 300+ bps below the FY22 peak because interest and depreciation on the capex debt have roughly doubled. For a multiple re-rating, margin expansion must move from cost-pull (resin) to volume-pull (utilisation 65% → 80%).

Quarterly trajectory — recovery is visible

Q3 FY25 was the earnings trough (₹13 Cr / 14% margin) — the US tariff scare at its worst. Three quarters later, margins hold a tight 19% band and net income has roughly doubled. 9M FY26 (₹691 Cr / ₹71 Cr NI) already beats full-year FY25 — hence the 52% six-month rally.

Cash generation — the inconvenient truth

Capital efficiency — Warren's question answered

Warren asked: genuine expansion or gold-plating? Genuine capacity — quartz sink line, steel sink ramp, solar — but priced as though the payback has already been earned. It has not. Asset turn on new capex is 1.2x vs Cera's asset-light ~3x. Until quartz utilisation moves 65% → 80%, Carysil runs Cera's balance-sheet intensity with Hindware's earnings volatility.

Balance sheet and leverage — still fine, but tighter

FY25 looks healthier than FY24 only because of a ₹168 Cr reserves injection (equity capital ₹5→₹6 Cr = ~5% share count expansion, almost certainly a QIP). That explains the promoter stake trim from 44% to 41.3% Warren flagged — dilution from a fresh issue, not a creeping sale. D/E at 0.42x is manageable; interest coverage 11x is comfortable.

Working capital — the hidden leverage

Inventory days blew out from 184 (FY23) to 290 (FY25) — roughly ₹250 Cr of working capital locked in finished sinks. Management says this is tariff-era staging plus new-plant stocking. If true, Q4 FY26 inventory days should revert toward 200; every 30 days released is ~₹70 Cr of cash back to ROCE. If false, write-down risk on stale SKUs.

Peer comparison — where Carysil actually sits

Cera is the anchor: 22% ROCE at 28x P/E. Carysil at 15% ROCE trades at essentially the same multiple — the market is paying Cera multiples for 30% lower ROCE, betting on mean reversion as utilisation climbs. Carysil needs ROCE ≥ 20% by FY27 to hold this valuation; if ROCE stays 15–17%, the stock derates to 20x ≈ ₹640.

Free-cash-flow adjusted valuation

Warren's FCF-adjusted valuation question. 198x P/FCF on reported FY25 is noise — FCF was working-capital suppressed. On 3-year avg FCF (~₹50 Cr) the multiple is ~52x, still 50–70% above Cera/Kajaria. EV/EBITDA at 14x is the one metric where Carysil looks cheap — it normalises the capex cycle and is how institutional buyers anchor the position.

Stress test — Warren's bear case quantified

Scenario construction (answering Warren Q3):

Bear (USA flat at tariff-era low, UK 0% growth): India grows 25% p.a., RoW 15% p.a., USA recovers only to 50% of FY25. Margin holds at 17%. FY27 EPS ≈ ₹33 — stock at ₹906 is a 27x multiple, not cheap in a bear outcome.

Base (UK flat, USA gradual recovery, India on plan): Revenue hits management's ₹1,200 Cr aspiration. Op margin ~19% as utilisation improves. FY27 EPS ≈ ₹46 — current price is a 20x multiple on FY27, reasonable for the asset.

Bull (volume leverage returns, 80%+ utilisation, India at ₹300 Cr+): FY27 EPS ≈ ₹60, stock re-rates to 25–28x = ₹1,500–₹1,680, upside ~65–85%.

The base case supports today's price; the upside is conditional on India executing; the downside is real if UK stays flat and tariff recovery stalls.

Ownership — the promoter dilution

Promoter stake dropped ~250 bps in Sep-24 as DII jumped 7% → 11%. Combined with the ₹168 Cr reserves bump, this was a QIP/preferential issue — not an on-market promoter sale. DII now ~12%, FII 1.6%; retail shareholder count fell 65k → 48k. Holder quality is improving.

The one metric watchlist

Closing view

What the numbers confirm: The FY26 margin recovery is real and printed three consecutive quarters in a row. Debt has come down, the balance sheet was recapitalised, institutional ownership is improving. At 14x TTM EV/EBITDA, this is not the most expensive way to own the Indian kitchen durables theme.

What the numbers contradict: The "brand transition / India pivot / compounder" narrative is not yet in the reported financials. ROCE has halved from the FY22 peak, FCF conversion is the weakest in the peer set, and ₹611 Cr of cumulative capex has produced ₹540 Cr of incremental revenue and essentially no incremental net income. On any fundamentals-based screen, this is a mid-cycle export manufacturer with capex overhang, not a compounder.

What must be watched next quarter: Q4 FY26 (May-26 release). Three gates: (1) Op margin ≥ 19% (tests margin durability); (2) Inventory days ≤ 250 (tests working-capital narrative); (3) 9M FY26 commentary on quartz-sink utilisation trajectory toward 80%. Miss any two of three and the stock de-rates to the ₹650–₹750 zone.